Factive-5 will be marketed in the territory by Pfizer Mexico which sublicensed the rights to develop and commercialize Factive in that country from Oscient in February of this year.
The antibiotic has been approved specifically for the treatment of community-acquired pneumonia (CAP), acute bacterial exacerbations of chronic bronchitis (AECB) and acute bacterial sinusitis (ABS).
“We expect to launch Factive-5, the most potent member of the fluoroquinolone class in vitro, into the over $900 million antibiotic market in Mexico in the coming weeks. We believe that Factive-5 offers an important therapeutic alternative for physicians and patients in Mexico,” stated Jorge Bracero, regional president and general manager, Northern Latin America, Pfizer.
Factive is currently approved in the US for the five-day treatment of AECB and the seven-day treatment of mild to moderate CAP.